Table 3.
Active Trials in SR-aGVHD
Response | Phase | Intervention | ||
---|---|---|---|---|
Itacitinib | 70.6% (30% CR) | Phase I | Itacitinib+Tocilizumab | NCT04070781 |
CD3/CD7-IT | 60%(50% CR) | Phase II | CD3/CD7-IT vs Ruxolitinib | NCT00640497 |
Neihulizumab | Skin only: 91% | Phase I | Neihilizumab | NCT03327857 |
FMT | Up to 100% | Phase II | FMT in GI aGVHD | NCT04059757 |
Abbreviation: FMT, fecal microbiota transplant.